Study evaluated the optimal duration of ledipasvir/sofosbuvir for the treatment of acute hepatitis C virus (HCV) infection in HIV.
Needle/syringe programs (NSPs) have proven to be effective and moderately effective in preventing transmission of HCV infection and minimizing drug-related harms among people who inject drugs in Europe and North America, respectively.
Daily cannabis use remained significantly associated with lower odds of steatosis even after adjustment for BMI, which is known to be inversely correlated with cannabis use.
The rates of anti-HCV orders and tests were collected from 4 medical specialties within a 30 mile radius of University of Michigan, Ann Arbor campus.
Glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an NS5A inhibitor, exhibit potent antiviral activity across all six major HCV genotypes.
Given the ongoing shortage of liver grafts, transplantation from HCV increased-risk donors to anti-HCV-negative recipients could potentially expand the donor pool.
The US VA has developed models of care that can be used to reduce the overall burden of HCV infection.
The high cost of DAA-based regimens remains an ethical issue and an obstacle to treatment accessibility. Shorter treatment regimens may offer substantial cost savings, improved treatment adherence, and a reduced rate of side effects.
Only a small percentage of people with HIV/HCV co-infection receive treatment for hepatitis C.
Researchers believe new once-daily dose of ravidasvir plus sofosbuvir is effective in treatment HCV genotype-4 and may be cost effective.
The majority of patients treated with second-generation direct-acting antiviral agents achieved sustained virologic response in 12 weeks.
Primary endpoints are to achieve sustained virologic response, improve survival rates, and lower complications of HCV.
Merck announced that the development programs for two hepatitis C virus infection treatments have been discontinued.
The American Association of the Study for Liver Diseases and the Infectious Diseases Society of America have added additional guidelines for the treatment of hepatitis C virus.
Mandating health care providers to offer hepatitis C virus screening can increase screening rates and linkage to care.
Despite continual efforts aimed at finding new treatment options, HCC still has a very low 5-year survival rate, less than 20%, as many patients are diagnosed at an advanced stage of the disease.
Researchers assessed safety and tolerability throughout the 12 week study period and 24 weeks after completion of last dose of glecaprevir coformulated with pibrentasvir.
Minimally effective treatment of hepatitis C virus can prevent th edevelopment of chronic kidney disease.
Researchers compared HbA1c changes and use of antidiabetic medication in HCV with diabetes.
The occurrence or recurrence risk for hepatocellular carcinoma is unclear after direct-acting antiviral agents and interferon based therapy.
Experts discuss screening, treatment, and other considerations in pediatric HCV.
Researchers compared the safety and efficacy of sofosbuvir plus ledipasvir vs pegylated interferon and ribavirin for 12 weeks in patients with thalassemia major and hepatitis C virus genotype 1 or 4.
HIV, hepatitis B, and hepatitis C infections are more prevalent among patients with severe mental illness than in the general population.
More interventions are needed to meet the target of hepatitis C virus elimination in the country of Georgia, defined as a 90% reduction in prevalence by 2020.
Non-specialists, including primary care providers and nurse practitioners, safely and effectively administer direct-acting antiviral therapy for hepatitis C virus to patients seen in FQHCs.
The FDA has approved an expanded indication for Epclusa to include the use of this once-daily single tablet regimen in patients co-infected with chronic hepatitis C virus and HIV.
Epidemiological data demonstrate a link between HCV infection and cardiovascular disease, whereas treatment studies suggest viral eradication may lower the risk for cardiovascular morbidity and mortality.
Steatosis, hypertension, older age, obesity, and HIV are risk factors for liver fibrosis in African-Americans with chronic hepatitis C.
Using an electronic health record-based can improve HCV screening rates among baby boomers.
FDA has approved Mavyret (glecaprevir and pibrentasvir) for the treatment of adults with chronic hepatitis C virus.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Are Antibiotic Stewardship Programs the Antidote to Antibiotic Overuse?
- Better Detection and Treatment Needed for H pylori Infections in Children
- FDA Approves New Hepatitis B Vaccine for Adults
- Strategies for Preventing Antibiotic Resistance in Acne
- Oral HPV Prevalence Higher in Men With Concurrent Genital HPV
- Study Finds Burnout Occurs in Over Half of US Surgeons
- HPV Vaccine Linked to Lower Respiratory Papillomatosis Rates
- Novel Antifungal Agent for Treatment of Aspergillus flavus Infections
- Inappropriate Antibiotic Use for Acute Bronchitis Highest in Younger Adults
- ACP, CDC Provides Best Practice Advice on Hepatitis B Management